# Orelabrutinib Therapy in Patients With r/r B-cell Lymphoma Intolerant to Other Bruton Tyrosine Kinase Inhibitors

> **NCT05495828** · — · UNKNOWN · sponsor: **Peking University People's Hospital** · enrollment: 30 (estimated)

## Conditions studied

- B-cell Lymphoma

## Interventions

- **DRUG:** Orelabrutinib

## Key facts

- **NCT ID:** NCT05495828
- **Lead sponsor:** Peking University People's Hospital
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-11-10
- **Primary completion:** 2024-12-10
- **Final completion:** 2025-03-10
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2023-10-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05495828

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05495828, "Orelabrutinib Therapy in Patients With r/r B-cell Lymphoma Intolerant to Other Bruton Tyrosine Kinase Inhibitors". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT05495828. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*